D2C health supplements clinically proven to deliver more of the good stuff to your body.
- Served more than 100,000 customers
- £4m+ annual revenue*
- £3m+ in annual recurring subscription revenue*
- More than 20x D2C revenue growth over last 4 years*
We sell clinically proven health supplements which improve lives, direct to consumers.
The health supplement sector has plenty of products, but little evidence of which products work, and which ones are right for you. This creates a confusing space for customers to navigate.
Our supplements work, and our customers evidence this by buying on subscription time and time again and by telling us their transformational stories.
Covid-19 has heightened consumers' awareness of the fact that we all need to take responsibility for our own health. At FutureYou Cambridge, we are investing in expanding our product ranges to serve even more people, as well as providing better digital tools to help our customers find the products they need.
Since we launched our brand, FutureYou Cambridge in 2016 we have sold to over 100,000 customers.
Substantial accomplishments to date
Built an experienced, heavyweight management team and board of directors, as well as an expert scientific advisory panel.
Consistently backed by influential private investors since our journey began in 2015.
IP-rich product base. Our key Lactolycopene patent was granted in Dec-2017.
Dedicated to high-quality products that produce scientifically proven results. For example, a clinical paper published in the European Journal of Nutrition in Oct-2019 showed that one of our Lactolycopene products (Fertility+) resulted in a 40% increase in fast-swimming sperm. Recognised in press worldwide.
Our in-house developed, bespoke, powerful, subscription management system is best in class.
First-class data analysis is central to our business success and informs everything we do.
Product range now at 24 products, including a popular CBD product and our first product for pets, Curcupet-K9 with 10+ further products planned to come in 2020.
Proven platform scalability, with >20x direct-to-consumer (DTC) revenue growth over the past 4 years, reaching total revenue of £4m+ in 2019*. We have now served >130,000 customers.
80% of our DTC revenue is repeating monthly subscription sales from our highly loyal customer base.
We have an industry-leading customer care team, winning the 2018 Cambridge Service Excellence and Independent High Growth Business of the Year awards.
Our 5-star Trustpilot review rating is testament to our first-rate customer service and high-quality products.
Around 90% of our sales are direct to consumer, with orders placed either through our website, by ongoing monthly subscription, or in some cases over the phone.
80% of our DTC revenue is from customers who have taken out a subscription. Although they can cancel at any time (and we make cancelling incredibly easy for them), they tend to be extremely loyal and consequently we see very high customer lifetime values.
As we have expended our product ranges and improved our targeted marketing messages, we see an increasing number of customers now purchasing more than one product from us.
We also sell to a few international partners in much larger, B2B transactions. Unlike D2C where transactions are typically £10-30, the scale of these transactions is £10,000-100,000 and they are less frequent. We aim to expand the list of partners we work with in overseas territories.
Use of proceeds
The business has no outstanding debt.
Funding is primarily allocated to scaling up direct advertising campaigns that already have great customer acquisition metrics, to further accelerate our business' growth.
We intend to expand our product range by more than 10 new products over the next twelve months, addressing two new customer segments, as well as expanding our offering across our existing segments. We believe that this will require an investment of £200,000 in additional inventory.
We also invest heavily in our website technology and have some exciting tools planned for customers to help them find the perfect supplements coming up in the next few months.
Based on scalability to date, we believe that doubling our revenue will require very few additional heads.
* Based on unaudited management accounts.
The company has two agreements with Nestec, a subsidiary of the Nestle Group: a license agreement and an option agreement.
• The agreement provides for mutual licensing arrangements between the Company and Nestec in respect of various patents held by both companies.
• Under these licences, the company pays a 5% royalty to Nestec on sales from products making up about 10% of overall revenue.
• To date, the company has never received any royalties from Nestec.
• The Nestec Option Agreement entitles Nestec to acquire up to 15% of the issued share capital of the Company (by way of new share issue) for a payment of up to £1.5m based on a £10m company valuation. The resultant Nestec maximum holding will be less than 15%, however, as it will be diluted by the issue of the Nestec shares themselves. Exercise of this option will dilute investors.
The licence agreement and the option agreement remain in force until the final patent expires on 13 April 2026.
Open an account to get access to the team members of FutureYou Cambridge
Already have an account? Log in
To comply with financial regulations, we can only show full campaign details to registered users.